Status:

TERMINATED

Safety and Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS)-Assisted Weight Loss

Lead Sponsor:

Elira Therapeutics, Inc.

Conditions:

Overweight

Obesity

Eligibility:

All Genders

18-65 years

Phase:

NA

Brief Summary

This study is a randomized, adaptive, parallel arm study. The treatment group will receive the Elira wearable patch system and provided instructions for use and advised to follow a 1200 calorie diet. ...

Detailed Description

This study employs a randomized, adaptive, parallel arm study in which, cohorts of enrolled subjects (25 per arm) are assessed for dose response and progression to achievement of primary and secondary...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Subject is between 18 - 65 years of age inclusive.
  • Subject has a BMI of 25-35 kg/ m\^2 inclusive.
  • Subject has signed the informed consent form and is able to comply with study protocol and adhere to study visit schedule.
  • Subject is able to wear and use a wearable, patch TENS system.
  • Subject is able to use a touch screen hand held smart phone.
  • Subject is fluent in English and can complete patient questionnaires.
  • Subject can comply with a 1200 calorie the recommended diet for the duration of the study.
  • Subject is male or non-pregnant, non-lactating female, who agrees to use effective contraceptive methods throughout the length of the trial based on PI approval.
  • Females of childbearing potential must have a negative urine pregnancy test at enrollment visit, prior to placement of ELIRA device.
  • Exclusion Criteria
  • Subject has any known gastrointestinal disorder that in the opinion of the PI precludes enrollment into the trial.
  • Subject has had a prior bariatric procedure.
  • Subject has any significant multisystem disease in the opinion of the PI.
  • Subject has \> 6.5 HbA1c.
  • Subject has significant cardiac arrhythmia, ectopy, or significant cardiovascular disease.
  • Subject has an existing implanted electrical stimulator (e.g., pacemaker, AICD).
  • Subject is a female of child-bearing potential who is pregnant or intends to become pregnant during the trial.
  • Subject has a history of any malignancy in the last 2 years.
  • Subject has had a weight change of + 5% of his/her Total Body Weight in the 3 months prior to enrollment.
  • Subject has a moderate / severe psychiatric disorder.
  • Subject has a diagnosed neurological disease.
  • Subject has a diagnosed eating disorder.
  • Subject has a skin disorder affecting the thoracic dermatomes.
  • Subject has abdominal surgery or other scars which may interfere with stimulation in the opinion of the PI.
  • Subject is currently enrolled in other, potentially confounding research.
  • Subject has known allergic reaction to materials in the electrodes and/or is otherwise unable to tolerate stimulation with the wearable TENS system.
  • Subject is actively participating or unwilling to discontinue participation in another weight loss program.
  • Subject is taking weight loss control medications including but not limited to OTC medications, Metformin, and Belviq.
  • Subject is unable to take anti-nausea medications planned for the study.
  • Inability to walk at least 0.8 kilometers per day (10 minutes of continuous walking).
  • Current smoker or user of nicotine product or smoking cessation within 1 year of the screening date.
  • History of treatment for or current abuse of drugs or alcohol.
  • A score of ≥10 on the Patient Health Questionnaire 9 (PHQ-9), demonstrating moderate depression.
  • Any subject that the investigator considers inappropriate for the study for medical reasons.
  • Subject has a history of migraine and/or is taking Topiramate for severe headache disorders.
  • Subject is on hormonal or other drug therapy which may alter antral motility or appetite, per physician discretion.

Exclusion

    Key Trial Info

    Start Date :

    September 5 2017

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    April 1 2018

    Estimated Enrollment :

    77 Patients enrolled

    Trial Details

    Trial ID

    NCT03299881

    Start Date

    September 5 2017

    End Date

    April 1 2018

    Last Update

    November 10 2021

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    St. Louis Women's Healthcare Group

    St Louis, Missouri, United States, 63017